The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated ...
The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...
The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...
Patients — and their doctors — have been desperate for a more effective pancreatic cancer treatment for decades. Now one ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...
Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” ...
After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...
The FDA has opened an expanded access program for daraxonrasib, an investigational drug showing encouraging results in pancreatic ductal adenocarcinoma with RAS mutations. Phase I/II trials reported ...
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results